Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US Government Contract Win

28 Feb 2013 07:00

RNS Number : 8492Y
Instem plc
28 February 2013
 

28 February 2013

 

Instem plc

("Instem", or, the "Company")

 

US Government Contract Win

 

Provantis Preclinical Software Chosen for National Toxicology Program by National Institute of Environmental Health Sciences

 

Instem (AIM:INS), a leading provider of IT solutions to the global early development healthcare market, announced today that the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health (NIH), has purchased the Provantis 9® preclinical software suite via SaaS (Software-as-a-Service) to support National Toxicology Program studies. These Reproductive, Immunotox, Neurobehavioural, Sensitisation and Carcinogenicity studies are primarily carried out at contractor laboratory sites throughout the United States.

 

The value of the award to Instem, funded completely by the US government, is approximately $870,000 in the first year, with potential to extend and expand the agreement up to a further 9 years, giving a possible total contract value for all 10 years of between $6.2m-$7.6m. The contract also includes the ability to expand to a larger number of additional sites on the same terms, which could result in further material increase in revenue.

 

The National Toxicology Program (NTP) is an interagency program established in 1978 to coordinate toxicology research and development across the Department of Health and Human Services. The program was also created to strengthen the science base in toxicology, develop and validate improved testing methods and provide information about potentially toxic chemicals to health regulatory and research agencies, scientific and medical communities, and the public.

 

Headquartered at NIEHS, the NTP is managed by the NIEHS and supported by the United States Food and Drug Administration and the Centers for Disease Control and Prevention.

 

Phil Reason, CEO of Instem plc, commented, "Such a significant contract with the US government, won through a competitive tendering process, is not only a fantastic endorsement of Instem's innovative software but also of our strategy to support collaborative working practices. Our SaaS delivery model enables the sharing of the software between dispersed communities from multiple organisations, The accessibility of Provantis data will also enable the National Institute of Environmental Health Sciences to meet a key goal of combining study information with a broader set of biology information to improve scientific insights.

 

"This long term contract will also provide funding for the development of the Provantis suite in areas specific to the National Toxicology Program, adding further depth to our market leading study management platform and positioning Instem well for anticipated contract extensions and any similar future projects."

 

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell

Joe Stroud

 

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

 

 

 

About Instem plc

 

Instem is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

 

Instem has over 130 customers in North America, Europe, Australia, China, India, Singapore and Japan, including 16 of the top 20 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and has a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software, making Instem an ideal partner to help unlock the scientific/commercial value from these legacy repositories.

 

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/

 

About NIEHS

The NIEHS supports research to understand the effects of the environment on human health and is part of the National Institutes of Health (NIH). Its mission is to reduce the burden of human illness and disability by understanding how the environment influences the development and progression of human disease.

 

For more information on environmental health topics, visit www.niehs.nih.gov.

 

The NIH - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

 

This project has been funded in whole or in part with Federal funds from the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN27320130004C.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTDXGDDSBDBGXR
Date   Source Headline
25th Feb 201610:17 amRNSHolding(s) in Company
23rd Feb 20161:32 pmRNSResult of General Meeting and Director Dealings
12th Feb 20167:00 amRNSInvestor Presentation
5th Feb 20164:47 pmRNSIssue of Equity and Total Voting Rights
4th Feb 20167:00 amRNSDirector/PDMR Shareholding
3rd Feb 20167:00 amRNSPlacing, Posting of Circular and Notice of GM
25th Jan 20167:00 amRNSInnovators & Investors Forum
13th Jan 20167:00 amRNSTrading Update
23rd Dec 20151:15 pmRNSDirector Shareholding and Other Holdings
8th Dec 20153:53 pmRNSIssue of Equity and Total Voting Rights
1st Dec 20157:00 amRNSLogos Earn Out, Issue of Equity and TVR
30th Nov 20155:59 pmRNSHolding(s) in Company
29th Sep 20157:00 amRNSHalf Yearly Report
6th Aug 201511:55 amRNSAdmission of Ordinary Shares
3rd Aug 20157:00 amRNSLogos Third Earn Out Payment & Total Voting Rights
30th Jul 20157:00 amRNSTrading Update and Notice of Interim Results
29th Jul 20157:01 amRNSGrants Under the Long Term Incentive Plan
23rd Jun 20157:00 amRNSInvestor Teach-in
21st May 20154:39 pmRNSHolding(s) in Company
19th May 20151:16 pmRNSResult of AGM
14th May 20157:00 amRNSInstem ALPHADAS Contract Wins
27th Apr 20159:16 amRNSPosting of Annual Report and Notice of AGM
30th Mar 20157:00 amRNSFinal Results
16th Mar 20157:00 amRNSNotice of Results
13th Feb 20157:00 amRNSPerceptive Instruments Earn Out Payment
27th Jan 20157:01 amRNSInnovators & Investors Forum (London)
12th Jan 20157:00 amRNSTrading Update and Notice of Results
23rd Dec 201411:52 amRNSHolding(s) in Company
18th Dec 20147:00 amRNSWIL Research Contract Extension
10th Nov 20147:00 amRNSCentrus-submit Contract Wins
24th Sep 20147:00 amRNSUnaudited Interim Results
5th Sep 20147:00 amRNSNotice of Results
13th Aug 201410:27 amRNSHolding(s) in Company
1st Aug 20147:00 amRNSLogos Second Earn Out Payment
16th Jul 20147:00 amRNSTwo contract wins in Asia-Pacific
21st May 201411:45 amRNSResult of AGM
1st May 20147:00 amRNSContract win
25th Apr 20147:00 amRNSPosting of Annual Report and Notice of AGM
26th Mar 20147:01 amRNSUS Government Contract Extension
26th Mar 20147:00 amRNSFinal Results
6th Mar 20147:00 amRNSNotice of Results
20th Feb 20147:00 amRNSThree-Year SaaS Contract with Leading Pharma
7th Feb 20141:05 pmRNSHolding(s) in Company
3rd Feb 20147:00 amRNSLogos Initial Earn Out Payment
8th Jan 20147:00 amRNSTrading Update and Notice of Results
22nd Nov 20137:00 amRNSAcquisition and Trading Update
9th Oct 20137:00 amRNSAppointment of VP Global Sales
25th Sep 20137:00 amRNSHalf Yearly Report
15th Aug 20137:00 amRNSNotice of Results
2nd Jul 20137:00 amRNSFirst Contract Win for Instem Clinical

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.